Get the Stockscreener App
12.85
0.16%
-0.02
After Hours:
12.59
-0.26
-2.02%
Stoke Therapeutics Inc stock is traded at $12.85, with a volume of 550.63K.
It is down -0.16% in the last 24 hours and up +13.22% over the past month.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.
See More
Previous Close:
$12.87
Open:
$12.778
24h Volume:
550.63K
Relative Volume:
0.83
Market Cap:
$701.57M
Revenue:
$8.78M
Net Income/Loss:
$-104.70M
P/E Ratio:
-5.4219
EPS:
-2.37
Net Cash Flow:
$-82.68M
1W Performance:
-4.89%
1M Performance:
+13.22%
6M Performance:
+11.93%
1Y Performance:
-14.16%
1-Day Range:
$12.54
$12.95
1-Week Range:
$12.25
$13.45
52-Week Range:
$5.35
$16.15
Stoke Therapeutics Inc Stock (STOK) Company Profile
Name
Stoke Therapeutics Inc
Sector
Industry
Phone
781-430-8200
Address
45 WIGGINS AVENUE, BEDFORD, MA
Compare STOK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
STOK
Stoke Therapeutics Inc
|
12.85 | 702.66M | 8.78M | -104.70M | -82.68M | -2.37 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.87 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.46 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.24 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
670.33 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
301.13 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Stoke Therapeutics Inc Stock (STOK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-18-25 | Initiated | Jefferies | Buy |
| Dec-20-24 | Initiated | Chardan Capital Markets | Buy |
| Oct-14-24 | Resumed | Leerink Partners | Outperform |
| Mar-26-24 | Upgrade | TD Cowen | Market Perform → Outperform |
| Nov-20-23 | Resumed | JP Morgan | Neutral |
| Jul-25-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| May-01-23 | Upgrade | BofA Securities | Underperform → Neutral |
| Apr-26-23 | Resumed | Canaccord Genuity | Buy |
| Jan-06-23 | Downgrade | BofA Securities | Buy → Underperform |
| Oct-24-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Jan-31-22 | Initiated | Jefferies | Buy |
| Dec-03-21 | Initiated | BofA Securities | Buy |
| Nov-22-21 | Upgrade | JP Morgan | Neutral → Overweight |
| May-18-21 | Initiated | UBS | Neutral |
| May-10-21 | Upgrade | Wedbush | Neutral → Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Feb-10-21 | Downgrade | Wedbush | Outperform → Neutral |
| Dec-15-20 | Resumed | H.C. Wainwright | Buy |
| Dec-11-20 | Reiterated | Needham | Buy |
| Oct-23-20 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-29-20 | Resumed | JP Morgan | Neutral |
| Sep-29-20 | Initiated | Needham | Buy |
| Dec-18-19 | Initiated | Wedbush | Outperform |
| Nov-12-19 | Initiated | BTIG Research | Buy |
| Oct-25-19 | Initiated | H.C. Wainwright | Buy |
| Jul-15-19 | Initiated | Canaccord Genuity | Buy |
| Jul-15-19 | Initiated | Cowen | Outperform |
| Jul-15-19 | Initiated | Credit Suisse | Outperform |
| Jul-15-19 | Initiated | JP Morgan | Overweight |
View All
Stoke Therapeutics Inc Stock (STOK) Latest News
Real time breakdown of Stoke Therapeutics Inc. stock performanceAI Trading Suggestions With Accuracy Focus Released - metal.it
Analysts Estimate Stoke Therapeutics, Inc. (STOK) to Report a Decline in Earnings: What to Look Out for - Yahoo Finance
Combining machine learning predictions for Stoke Therapeutics Inc.Free Sector Based Breakout Stock Forecast - Newser
Bullish Candlestick Pattern Forms in Stoke Therapeutics Inc.Sector Based Breakout Stock Forecast Issued - metal.it
Multi asset correlation models including Stoke Therapeutics Inc.Entry Zone Forecast for Momentum Trading - Newser
Price Channel Expanding on Stoke Therapeutics Inc.’s ChartTrade Setups With AI Powered Filters Published - metal.it
What moving averages say about Stoke Therapeutics Inc.Low Risk High Confidence Watchlist Builder - Newser
When is Stoke Therapeutics Inc. stock expected to show significant growthPost Market Picks With Low Risk - jammulinksnews.com
Is Stoke Therapeutics Inc. a growth stock or a value stockGet timely alerts on market movers - jammulinksnews.com
What makes Stoke Therapeutics Inc. stock price move sharplyInvest confidently with actionable market data - jammulinksnews.com
Is Stoke Therapeutics Inc. Stock a Good Fit for Conservative Investors Technical Screener for High Growth Stocks - metal.it
Is it the right time to buy Stoke Therapeutics Inc. stockExpert guidance for superior capital growth - jammulinksnews.com
Stoke Therapeutics Inc. Company’s Quarterly Earnings Growth: What the Numbers SayPredictable High Return Trades - metal.it
Should I hold or sell Stoke Therapeutics Inc. stock in 2025Earnings Report Alerts For Every Investor - jammulinksnews.com
How strong is Stoke Therapeutics Inc. company’s balance sheetUnlock exclusive investment alerts - jammulinksnews.com
How volatile is Stoke Therapeutics Inc. stock compared to the marketSuperior return velocity - jammulinksnews.com
What are analysts’ price targets for Stoke Therapeutics Inc. in the next 12 monthsDiscover market opportunities others miss - jammulinksnews.com
How does Stoke Therapeutics Inc. generate profit in a changing economyInvest smarter with actionable market insights - jammulinksnews.com
How does Stoke Therapeutics Inc. compare to its industry peersBuild wealth with steady, reliable stocks - jammulinksnews.com
Stoke Therapeutics Inc. Stock Analysis and ForecastFree High-Return Strategy Alerts - PrintWeekIndia
Is Stoke Therapeutics Inc. a good long term investmentSuperior return velocity - Autocar Professional
What analysts say about Stoke Therapeutics Inc. stockExtraordinary market timing - Autocar Professional
Biogen Inc. (BIIB) Partners with Stoke Therapeutics to Tackle Dravet Syndrome - MSN
Stoke Therapeutics Bets Big On Rare Disease Therapies - Finimize
Stoke Therapeutics Soars 17.02% on Market Optimism - AInvest
What drives Stoke Therapeutics Inc. stock priceRobust investment performance - jammulinksnews.com
Why Stoke Therapeutics Inc. stock attracts strong analyst attentionProven Return Strategy Execution - Newser
Published on: 2025-07-22 15:57:09 - jammulinksnews.com
Published on: 2025-07-22 13:02:52 - jammulinksnews.com
Jefferies Financial Group Begins Coverage on Stoke Therapeutics (NASDAQ:STOK) - Defense World
How to Take Advantage of moves in (STOK) - news.stocktradersdaily.com
Is Stoke Therapeutics, Inc.'s (NASDAQ:STOK) Recent Stock Performance Influenced By Its Fundamentals In Any Way? - 富途牛牛
Stoke Therapeutics Inc Stock (STOK) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.43%
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):